Actinium Pharma’s stock craters after FDA says Phase 3 trial of leukemia treatment not enough for BLA
The stock of biotech Actinium Pharmaceutics Inc. tumbled 65% early Monday, after the Food and Drug Administration said a late-stage trial of its Iomab-B leukemia treatment is not enough to support a request for approval.